A Phase 1/2 Study of RAD001 in Combination w/ Cetuximab and Cisplatin as First-line Therapy in Recurrent and Metastatic Squamous Cell Cancer of the Head and Neck.
Phase of Trial: Phase I/II
Latest Information Update: 22 Feb 2017
At a glance
- Drugs Everolimus (Primary) ; Carboplatin; Cetuximab; Cisplatin
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 15 Aug 2011 Planned end date changed from 1 Jan 2014 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 21 Apr 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.